logo
Jim Cramer Says Williams-Sonoma's CEO 'Moved a Ton of Manufacturing to Vietnam'

Jim Cramer Says Williams-Sonoma's CEO 'Moved a Ton of Manufacturing to Vietnam'

Yahoo05-07-2025
Williams-Sonoma, Inc. (NYSE:WSM) is one of the 22 stocks Jim Cramer recently talked about. Coming to the company, Cramer stated:
'Laura Alber, CEO of Williams-Sonoma, moved a ton of manufacturing to Vietnam. Her stock's down more than 6% for the year, intriguing. [It] jumped more than 2% on the tariff news, but that's nothing.'
An interior of a modern home with a wide selection of cookware, tools and cutlery on display.
Williams-Sonoma (NYSE:WSM) sells a wide range of home products, including cookware, furniture, decor, and personalized items, through both digital and physical retail channels. Additionally, the company operates a 3-D imaging and augmented reality platform for home design. Vltava Fund stated the following regarding Williams-Sonoma, Inc. (NYSE:WSM) in its Q1 2025 investor letter:
'We sold the rest of the Williams-Sonoma, Inc. (NYSE:WSM) stock. This was a very profitable investment for us. How do we evaluate its feedback? We did not hold the stock for very long, only about 3-1/2 years. During that time, the stock price moved from less than $50 to more than $200. In the beginning, we could buy the shares at single digit earnings multiples. The stock price was well below our estimate of the company's value. The business itself is of very high quality, with high returns on capital, no debt, and an exemplary asset allocation. As such, we see the purchase itself as a good move and entirely in line with our investment philosophy. When we sold the shares, they were trading at about 25 times earnings. This was significantly higher than our current estimate of the company's value. Any company, however good and promising it may appear, is a good investment at a low price but a poor investment at a high price. We are always reminded of this and therefore we sold the WSM shares. So far, we see this also as a good move and entirely consistent with our investment philosophy. At the same time, however, we are aware that the large total return on this investment was only partly the result of our transactions and analysis. Luck also played a large part. We expected that WSM would do well in its business. This was confirmed, and the shares also had been objectively very cheap when we bought them. However, all of this falls far short of justifying the rapid quadrupling of the share price. We therefore do not succumb to the temptation to attribute more to our own skills than is prudent. It remains important for us to stick to our investment philosophy and investment process in our stock selection and individual transactions. On average and over the longer term, they should continue to bring us solid returns, although in individual cases or over shorter periods they may deliver returns both much better than they deserve and much poorer than they deserve.'
While we acknowledge the potential of WSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Yahoo

time18 minutes ago

  • Yahoo

Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio

CONMED (CNMD) Q2 Earnings: What To Expect
CONMED (CNMD) Q2 Earnings: What To Expect

Yahoo

time18 minutes ago

  • Yahoo

CONMED (CNMD) Q2 Earnings: What To Expect

Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings

Yahoo

time18 minutes ago

  • Yahoo

Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings

Packaged foods company Kraft Heinz (NASDAQ:KHC) will be reporting results this Wednesday before market open. Here's what investors should know. Kraft Heinz met analysts' revenue expectations last quarter, reporting revenues of $6.00 billion, down 6.4% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' EBITDA estimates but full-year EPS guidance missing analysts' expectations. Is Kraft Heinz a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Kraft Heinz's revenue to decline 3.1% year on year to $6.27 billion, in line with the 3.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.64 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 10 analysts). Looking at Kraft Heinz's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lamb Weston delivered year-on-year revenue growth of 4%, beating analysts' expectations by 5.7%, and McCormick reported flat revenue, in line with consensus estimates. Lamb Weston traded up 19.3% following the results while McCormick was also up 3.6%. Read our full analysis of Lamb Weston's results here and McCormick's results here. There has been positive sentiment among investors in the shelf-stable food segment, with share prices up 3.8% on average over the last month. Kraft Heinz is up 9.3% during the same time and is heading into earnings with an average analyst price target of $30.18 (compared to the current share price of $28.22). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store